U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Immune Checkpoint Inhibitor-Induced Dermatitis

MedGen UID:
1784079
•Concept ID:
C5447550
•
Disease or Syndrome
Synonym: ICI-Induced Dermatitis

Definition

Dermatitis associated with the therapeutic use of an immune checkpoint inhibitor. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVImmune Checkpoint Inhibitor-Induced Dermatitis

Recent clinical studies

Etiology

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report.
Powers CM, Verma H, Orloff J, Piontkowski AJ, Tiersten A, Lamb A, Gulati N
J Dermatolog Treat 2024 Dec;35(1):2336118. Epub 2024 Apr 2 doi: 10.1080/09546634.2024.2336118. PMID: 38565207
PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
Moore DC, Elmes JB, Arnall JR, Strassel SA, Patel JN
Int Immunopharmacol 2024 Mar 10;129:111606. Epub 2024 Feb 14 doi: 10.1016/j.intimp.2024.111606. PMID: 38359661

Diagnosis

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report.
Powers CM, Verma H, Orloff J, Piontkowski AJ, Tiersten A, Lamb A, Gulati N
J Dermatolog Treat 2024 Dec;35(1):2336118. Epub 2024 Apr 2 doi: 10.1080/09546634.2024.2336118. PMID: 38565207
PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
Moore DC, Elmes JB, Arnall JR, Strassel SA, Patel JN
Int Immunopharmacol 2024 Mar 10;129:111606. Epub 2024 Feb 14 doi: 10.1016/j.intimp.2024.111606. PMID: 38359661
Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review.
Zhang L, Wang L, Cheng Q, Lei X, Wu J, Chen N
Immunotherapy 2023 Oct;15(15):1249-1256. Epub 2023 Aug 10 doi: 10.2217/imt-2023-0081. PMID: 37585673

Therapy

PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
Moore DC, Elmes JB, Arnall JR, Strassel SA, Patel JN
Int Immunopharmacol 2024 Mar 10;129:111606. Epub 2024 Feb 14 doi: 10.1016/j.intimp.2024.111606. PMID: 38359661
Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.
Satoh TK, Neulinger MM, Stadler PC, Aoki R, French LE
J Dermatol 2024 Jan;51(1):3-11. Epub 2023 Nov 30 doi: 10.1111/1346-8138.17039. PMID: 38031902
Immune checkpoint inhibitor-induced lichenoid drug eruption-sparing scar burns.
Truong K, Chamberlin CV, Kim J, Carlino MS, Araujo RR
Australas J Dermatol 2024 Mar;65(2):163-166. Epub 2023 Nov 27 doi: 10.1111/ajd.14192. PMID: 38009870
Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review.
Zhang L, Wang L, Cheng Q, Lei X, Wu J, Chen N
Immunotherapy 2023 Oct;15(15):1249-1256. Epub 2023 Aug 10 doi: 10.2217/imt-2023-0081. PMID: 37585673
Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.
Guo Q, Gao J, Guo H, Xie J, Cheng J
Int Immunopharmacol 2023 Jan;114:109490. Epub 2022 Nov 29 doi: 10.1016/j.intimp.2022.109490. PMID: 36459923

Prognosis

Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.
Popa LG, Giurcaneanu C, Portelli MG, Mihai MM, Beiu C, Orzan OA, Ion A, Anghel TH
Medicina (Kaunas) 2024 Feb 22;60(3) doi: 10.3390/medicina60030373. PMID: 38541099Free PMC Article
Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.
Satoh TK, Neulinger MM, Stadler PC, Aoki R, French LE
J Dermatol 2024 Jan;51(1):3-11. Epub 2023 Nov 30 doi: 10.1111/1346-8138.17039. PMID: 38031902

Clinical prediction guides

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report.
Powers CM, Verma H, Orloff J, Piontkowski AJ, Tiersten A, Lamb A, Gulati N
J Dermatolog Treat 2024 Dec;35(1):2336118. Epub 2024 Apr 2 doi: 10.1080/09546634.2024.2336118. PMID: 38565207
PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
Moore DC, Elmes JB, Arnall JR, Strassel SA, Patel JN
Int Immunopharmacol 2024 Mar 10;129:111606. Epub 2024 Feb 14 doi: 10.1016/j.intimp.2024.111606. PMID: 38359661
Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.
Satoh TK, Neulinger MM, Stadler PC, Aoki R, French LE
J Dermatol 2024 Jan;51(1):3-11. Epub 2023 Nov 30 doi: 10.1111/1346-8138.17039. PMID: 38031902
Immune checkpoint inhibitor-induced lichenoid drug eruption-sparing scar burns.
Truong K, Chamberlin CV, Kim J, Carlino MS, Araujo RR
Australas J Dermatol 2024 Mar;65(2):163-166. Epub 2023 Nov 27 doi: 10.1111/ajd.14192. PMID: 38009870

Recent systematic reviews

PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
Moore DC, Elmes JB, Arnall JR, Strassel SA, Patel JN
Int Immunopharmacol 2024 Mar 10;129:111606. Epub 2024 Feb 14 doi: 10.1016/j.intimp.2024.111606. PMID: 38359661

Supplemental Content

Table of contents

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...